论文部分内容阅读
目的 :评价诺维本 (NVB)与顺铂 (DDP)联合治疗非小细胞肺癌 (NSCL C)的近期疗效和不良反应。方法 :对 45例中晚期 NSCLC患者进行 NVB+DDP联合化疗 ,NVB2 5 mg/ m2 d1 、d8,DDP2 0 mg/ m2 d1 ～ d5,每 3～ 4周为 1周期 ,所有患者均完成 2周期以上化疗方可评价疗效。结果 :全组有效率为 2 8.9% ,其中 期患者有效率为 45 % , 期患者有效率为 1 6% ,两者间有显著性差异 ,其不良反应为白细胞降低和静脉炎。结论 :NVB+DDP方案治疗 NSCLC有较好的疗效 ,白细胞降低是其主要的剂量限制性毒性
Objective: To evaluate the short-term efficacy and side effects of combination of NVB and DDP in the treatment of non-small cell lung cancer (NSCL C). Methods: Forty-five patients with advanced non-small cell lung cancer (NSCLC) undergoing NVB + DDP combined with chemotherapy were treated with NVB2 5 mg / m2 d1, d8 and DDP2 0 mg / m2 d1 ~ d5 every 3 to 4 weeks. All patients completed more than 2 cycles Chemotherapy can be evaluated efficacy. Results: The effective rate of the whole group was 29.9%. The effective rate was 45% in the mid-term and 16% in the moderate stage. There was a significant difference between the two groups. The adverse reactions were leukopenia and phlebitis. Conclusion: The treatment of NSCLC with NVB + DDP has a good curative effect. Leukopenia is the main dose-limiting toxicity